PEPFAR's annual planning process is done either at the country (COP) or regional level (ROP).
PEPFAR's programs are implemented through implementing partners who apply for funding based on PEPFAR's published Requests for Applications.
Since 2010, PEPFAR COPs have grouped implementing partners according to an organizational type. We have retroactively applied these classifications to earlier years in the database as well.
Also called "Strategic Areas", these are general areas of HIV programming. Each program area has several corresponding budget codes.
Specific areas of HIV programming. Budget Codes are the lowest level of spending data available.
Expenditure Program Areas track general areas of PEPFAR expenditure.
Expenditure Sub-Program Areas track more specific PEPFAR expenditures.
Object classes provide highly specific ways that implementing partners are spending PEPFAR funds on programming.
Cross-cutting attributions are areas of PEPFAR programming that contribute across several program areas. They contain limited indicative information related to aspects such as human resources, health infrastructure, or key populations programming. However, they represent only a small proportion of the total funds that PEPFAR allocates through the COP process. Additionally, they have changed significantly over the years. As such, analysis and interpretation of these data should be approached carefully. Learn more
Beneficiary Expenditure data identify how PEPFAR programming is targeted at reaching different populations.
Sub-Beneficiary Expenditure data highlight more specific populations targeted for HIV prevention and treatment interventions.
PEPFAR sets targets using the Monitoring, Evaluation, and Reporting (MER) System - documentation for which can be found on PEPFAR's website at https://www.pepfar.gov/reports/guidance/. As with most data on this website, the targets here have been extracted from the COP documents. Targets are for the fiscal year following each COP year, such that selecting 2016 will access targets for FY2017. This feature is currently experimental and should be used for exploratory purposes only at present.
Years of mechanism: 2010 2011 2012 2013 2014 2015
The Supply Chain Management Systems (SCMS) Project (USAID Contract #GPO-I-00-05-00032-00) brings together a partnership of 16 private sector, nongovernmental and faith-based organizations that are among the most trusted names in supply chain management and international public health and development. With offices in 17 countries and 350 dedicated staff members around the world, SCMS is helping to improve the lives of people living with HIV/AIDS in some of the countries most severely impacted by the pandemic. SCMS procures essential medicines and supplies at affordable prices; helps strengthen and build reliable, secure and sustainable supply chains systems; and fosters coordination of key stakeholders.
In Zimbabwe, the SCMS Project is implemented by JSI Research & Training Institute Inc, one of the 16 project partners. SCMS procures first line ARV drugs for approximately 59,000 adult patients. SCMS strengthens MOHCW, NatPharm and ZNFPC capacity in supply chain management through technical assistance and operations support which includes the design and implementation of distribution and LMIS systems; provision of staff to the MOHCW; provision of delivery and monitoring vehicles, fuel and maintenance; training in forecasting and quantification; an ARV stock audit system; support for warehousing improvements, and support for donor coordination. Additionally, the project strengthens MOHCW technical ART capacity by providing two key staff to the national ART program.
The program will strengthen Zimbabwe's human resources for health in FY10 by conducting a full, in-depth course in Supply Chain Logistics, training on PipeLine Software, and updated trainings on the ARV Pull System. Additionally, the project will support decentralization training by the AIDS & TB Program for HIV care providers.
In FY 2010, SCMS will continue to second two medical officer positions to MOHCW AIDS & TB Programme: the National ART Coordinator and the Assistant National ART Coordinator. The project's support will include funding of site readiness assessments and site supervision aimed at enhancing the MOHCW's ART scale-up activities, the national quality of care initiative, and decentralization of ARV treatment. SCMS will continue to support supply chain systems which ensure that the ART treatment sites have an adequate supply of ARV drugs.
In FY 2009 and 2010, SCMS will continue to procure up to approximately $200,000 of HIV rapid tests (Determine, SD Bioline, and the INsti tie breaker rapid tests under the current parallel testing algorithm) to contribute to the achievement of the MOHCW targets,(1,200,000 adults and children to be tested in CY 2011) and will assist the MOHCW in accurately quantifying HIV rapid test kit requirements. The national program's stated intention to move to a serial HIV testing protocol, originally targeted for June 2008, is not projected to begin until 2010.
Distribution for the rapid tests is part of SCMS's OHSS activities.
In FY 2010, SCMS will continue to support operation and maintenance of the Logistics Management Information System (LMIS), Zimbabwe Information System for HIVAIDS Commodities (ZISHAC), managed by the MOHCW/AIDS & TB's Logistics Sub-Unit. The system captures patient data, consumption, stock on hand and losses and adjustment data, all used for informed quantification, storage and distribution decision-making.
In addition to ZISHAC, SCMS plans to support an expanded version of the ARV stock audit of USG-funded ARVs, completed at the central level in FY2009. The expanded audit will include ARVs funded by all donors and managed by the MOHCW system and cover central level and ART site level on a sample basis.
With FY2009 Supplemental funding and In FY 2010, SCMS will provide ongoing technical assistance and resource support to the MOHCW/AIDS & TB Logistics sub-unit (LSU). The fourteen current staff positions of the LSU are funded through SCMS, as is the SCM Coordinator based at the MOHCW/AIDS & TB Unit.
The LSU manages the supply chain for the national MOHCW ART program. The LSU, along with the Directorate of Pharmacy Services (DPS), chairs the Procurement and Logistics Sub-committee of the ART Partners Forum, a central body for donor and partner collaboration and communication. SCMS, through the LSU, will continue to provide the following:
Product Selection: review national treatment guidelines, offer logistics considerations of choosing products, and work to minimize pack size proliferation.
Quantification/Forecasting /Supply Planning: lead and manage quarterly updates of quantifications for Adult and Paediatrics ARV drugs fro treatment and PMTCT, HIV test kits, TB drugs, cotrimoxazole, and fluconazole.
Procurement: prepare procurement plans for all USG funded products; assist other partners in the development of procurement plans; highlight supply gaps and mobilize resources to fill these gaps.
Warehousing: work with NatPharm (parastatal storage agent for all MOHCW HIV & AIDS commodities) to address any existing or potential storage challenges. In 2009, SCMS seconded a part-time project coordinator to NatPharm to assist with the ESP-funded purchase and installation of a racking system, a radiation heat barrier to preserve MOHCW ARVs and a new roof. SCMS plans to provide the same level of support to Phase II of the refurbishment in FY10.
Distribution: support NatPharm with national bi-monthly distribution of ARV drugs and OI drugs, providing 3 delivery trucks, fuel and maintenance, drivers, and per diem.SCMS will also continue to assist the MOHCW in implementing an ordering and distribution system for rapid tests to ensure their availability to the public for roughly $500,000 per year, with an additional $500,000 in supplemental funding for PMTCT MER roll-out on the same system. HIV rapid tests and PMTCT NVP, followed by a pilot of the PMTCT MER, were added to the ZNFPC DTTU system in 2009.
Capacity Building: provide system-specific training on logistics for ART sites as necessitated by addition of new sites and personnel attrition, as well as trainings to personnel in associated delivery systems like ZNFPC's DTTU.
In FY 2010, up to $300,000 will be used for the procurement of point of care (POC) rapid CD4 testing machines and reagents or other products as necessary to increase the numbers of pregnant women initiated to ART.
During 2009, MOHCW revised the PMTCT strategy to progressively increase the proportion of pregnant women who received more efficacious regimens (MER). It is expected 15,000 mother/infants receive PMTCT MER in 2010 and 25,000 mother/infants in 2011. Part of the ARVs needed will be supplied by UNITAID; the balance being supplied by SCMS that will provide MER ARVs for 4,200 (2010) and 4,500 (2011) mother/infants.
With FY 2009 supplemental funds, SCMS will purchase an additional $1,880,000 worth of ARVs to support treatment of an additional 19,000 adult on standard 1st line regimen on a temporary basis, to fill gap caused by delays in GF funding and procurement.
In FY 2010, SCMS will provide first-line ARVs to continue the provision of ARVs worth $4,000,000 initiated in 2007 for 40,000 adult patients treated in public sector health facilities . An additional $1,625,000 will be used to help MOHCW address temporary gaps in 1st line ARV funding and avoid stock outs that could lead to treatment disruption. SCMS supplied ARVs will contribute to meeting the MOHCW target (310,000 adult ART patients by the end of 2011) which is also supported by the Government of Zimbabwe, Global Fund, the DFID-led Expanded Support Programme, the Clinton Foundation, EU, UNITAID and other donors such as Direct Relief International and Axios/Abbot.
To support these patients and in accordance with the MOHCW Guidelines for ARV Therapy in Zimbabwe, SCMS will procure the following medicines: Lamivudine/Stavudine/Nevirapine 150/30/200mg for patients on the standard first line regimen, Lamivudine/Stavudine 150/30mg and Efavirenz 600mg for first line patients with tuberculosis and Lamivudine-Zidovudine 150+300mg plus Nevirapine 200mg for pregnant women. These drugs will be FDA-approved/tentatively-approved generics, whenever possible and logical.
